Tianjin Pharmaceuticals Group is a state-owned large-scale comprehensive pharmaceutical conglomerate established in 1979. The company operates within four primary sectors, including chemical and biopharmaceuticals, green Chinese medicine, high-end medical equipment, and modern commercial logistics. With over 100 subsidiaries, it has strategically invested in three newly listed companies: Sino-Singapore, Tianyao, and Lisheng Pharmaceutical. Additionally, the organization has formed over 10 joint ventures with various multinational pharmaceutical corporations. Tianjin Pharmaceuticals Group consistently achieves top rankings in China's pharmaceutical industry based on key economic indicators and has been recognized among the top 500 Chinese companies for several years.
As a venture capital entity, the notable performance and diverse portfolio of Tianjin Pharmaceuticals Group present an attractive investment opportunity in the pharmaceutical industry. Its extensive network of subsidiaries and joint ventures offers potential for strategic partnerships and collaborations. The consistent top-ranking status in China's pharmaceutical sector demonstrates the company's stability and growth potential, making it an appealing prospect for investment. Furthermore, the company's ongoing investments in innovative pharmaceutical companies such as Sino-Singapore, Tianyao, and Lisheng Pharmaceutical highlight its commitment to expanding and diversifying its portfolio.
There is no investment information
No recent news or press coverage available for Tianjin Pharmaceuticals Group.
We care about your data, and we'd love to use cookies make your experience better.
